João Β. Calixto

ORCID: 0000-0003-4041-7153
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Pain Mechanisms and Treatments
  • Neuropeptides and Animal Physiology
  • Mast cells and histamine
  • Pharmacological Effects of Natural Compounds
  • Phytochemistry and Bioactivity Studies
  • Natural product bioactivities and synthesis
  • Nitric Oxide and Endothelin Effects
  • Ion channel regulation and function
  • Neuroendocrine regulation and behavior
  • Ion Channels and Receptors
  • Receptor Mechanisms and Signaling
  • Phytochemistry and Biological Activities
  • Neuroscience and Neuropharmacology Research
  • Phytochemistry and Bioactive Compounds
  • Essential Oils and Antimicrobial Activity
  • Chemical synthesis and alkaloids
  • Phytochemical compounds biological activities
  • Plant Toxicity and Pharmacological Properties
  • Nerve injury and regeneration
  • Traditional and Medicinal Uses of Annonaceae
  • Asthma and respiratory diseases
  • Adenosine and Purinergic Signaling
  • Alzheimer's disease research and treatments
  • Blood Coagulation and Thrombosis Mechanisms

Centro de Pesquisas Oncológicas
2014-2025

Universidade Federal de Santa Catarina
2010-2023

Polydoro Ernani de São Thiago University Hospital
2014

Centro de Excelência em Bioinformática
2008

Istituto di Farmacologia Traslazionale
2006-2007

Technical Design (United States)
2005

Universidade Federal de São Paulo
2000-2004

Queen Mary University of London
2003

Universidade do Vale do Itajaí
1996-2002

Community Farm Alliance
2001

The global medicine market is about 1.1 trillion US dollars. About 35 percent of medicines have originated from natural products. Brazil presents the largest biodiversity in world, with more than 50,000 species higher plants. However, few innovative products been developed active constituents derived Brazilian biodiversity. Scientific evidences on plants and venoms internationally published by scientists over last 4 decades; but examples are commercially available. Few include...

10.1590/0001-3765201920190105 article EN cc-by Anais da Academia Brasileira de Ciências 2019-01-01

10.1016/j.jep.2005.06.004 article EN Journal of Ethnopharmacology 2005-07-13

Abstract It has been previously reported that dietary fish oils, which are rich in the polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic acid, can exert beneficial effects inflammatory bowel disease. In this study, we investigated of acid–derived lipid mediator maresin 1 (MaR1) dextran sulfate sodium (DSS)– 2,4,6-trinitrobenzenesulfonic acid–induced colitis mice. Systemic treatment with MaR1 significantly attenuated both DSS- 2,4,6-trinitrobenzene sulfonic colonic...

10.4049/jimmunol.1202743 article EN The Journal of Immunology 2013-09-14

Resolvins of the D series are generated from docosahexaenoic acid, which enriched in fish oils and believed to exert beneficial roles on diverse inflammatory disorders, including bowel disease (IBD). In this study, we investigated anti-inflammatory effects aspirin-triggered resolvin D1 (AT-RvD1), its precursor (17(R)-hydroxy acid [17R-HDHA]) D2 (RvD2) dextran sulfate sodium (DSS)- or 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Our results showed that systemic treatment with AT-RvD1,...

10.4049/jimmunol.1101305 article EN The Journal of Immunology 2011-07-04

Kinins are important mediators in cardiovascular homeostasis, inflammation, and nociception. Two kinin receptors have been described, B1 B2. The B2 receptor is constitutively expressed, its targeted disruption leads to salt-sensitive hypertension altered a heptahelical distinct from the that it highly inducible by inflammatory such as bacterial lipopolysaccharide interleukins. To clarify physiological function, we generated mice with deletion of gene for receptor. receptor-deficient animals...

10.1073/pnas.120035997 article EN Proceedings of the National Academy of Sciences 2000-06-20

Increased brain deposition of amyloid β protein (Aβ) and cognitive deficits are classical signals Alzheimer's disease (AD) that have been highly associated with inflammatory alterations. The present work was designed to determine the correlation between tumor necrosis factor-α (TNF-α)-related signaling pathways inducible nitric oxide synthase (iNOS) expression in a mouse model AD, by means both vivo vitro approaches. intracerebroventricular injection Aβ 1–40 mice resulted marked learning...

10.1523/jneurosci.5047-06.2007 article EN cc-by-nc-sa Journal of Neuroscience 2007-05-16

This study was designed to investigate the role of bradykinin (BK), as well subtype BK receptors involved, in formalin‐induced hindpaw pain mouse by use selective B 1 and 2 receptor antagonists. In addition, we have analysed whether or not may be involved oedema mouse. The pretreatment animals with captopril (2 5 mg kg −1 , s.c.) significantly increase first second phases pain. Co‐injection antagonist des‐Arg 9 [Leu 8 ]‐BK (0.2–0.4 nmol/paw), together formalin, caused graded similar...

10.1111/j.1476-5381.1993.tb13791.x article EN British Journal of Pharmacology 1993-09-01

This study investigated the role of TRPA1 in development and maintenance mechanical cold hyperalgesia persistent inflammation induced by Complete Freund's Adjuvant (CFA) mice. The intraplantar (i.pl.) injection CFA a long lasting (28 days) for both thermal (cold) stimuli. intraperitoneal (i.p., 30-300 mg/kg), (i.pl., 100 microg/site) or intrathecal (i.t., 10 selective antagonist HC-030031 significantly reduced evaluated von Frey hair test. effect was evidenced on day after kept throughout...

10.1016/j.pain.2009.12.002 article EN Pain 2009-12-29

Resolution of inflammation is mediated by endogenous molecules with anti-inflammatory and pro-resolving activities they have generated new possibilities for the treatment inflammatory diseases. Here, we investigated possible anti-hyperalgesic effects two lipids, aspirin-triggered resolvin D1 (AT-RvD1) its precursor, 17(R)-hydroxy-4Z,7Z,10Z,13Z,15E,17R,19Z-docosahexaenoic acid (17(R)HDoHE).

10.1111/j.1476-5381.2011.01345.x article EN British Journal of Pharmacology 2011-03-21
Coming Soon ...